EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cellular and molecular responses of Cryptococcus to brilacidin

Barbara T Bezerra, Daniel A Mellon, Cássia M Souza, Rafael F Castelli, Amanda C Camillo-Andrade, Marlon D M Santos, Paulo C Carvalho iD, Marcio L Rodrigues iD, Haroldo C de Oliveira iD

Microbiology Spectrum · 2026

DOI: 10.1128/spectrum.00138-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2026. Verfasst von Barbara T Bezerra und 8 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Carlos Chagas, Fundação Oswaldo Cruz (Fiocruz), Curitiba, Brazil. Hauptthemen laut MEDLINE: Antifungal Agents, Cryptococcus neoformans, Cryptococcosis, Cryptococcus. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, National Institute of Allergy and Infectious Diseases, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cryptococcosis is a systemic mycosis caused by Cryptococcus neoformans and Cryptococcus deuterogattii . Available therapeutic options are limited and face several challenges, including toxicity, the emergence of resistant strains, high costs, and restricted distribution. In this study, we explored the cellular and molecular responses of Cryptococcus spp. to brilacidin, a recently characterized fungicidal agent with promising potential for the treatment of cryptococcosis. Brilacidin exhibited inhibitory activity with a minimum inhibitory concentration of 2.5 µM and demonstrated a high selectivity index and low cytotoxicity in murine macrophages. Synergy assays revealed that brilacidin potentiated amphotericin B activity, reducing its effective dose up to eightfold without increasing cytotoxicity. Morphological analyses by scanning, confocal, and transmission electron microscopy expanded previously described effects of brilacidin and revealed profound alterations in capsule structure, plasma membrane integrity, and intracellular organization. Brilacidin also inhibited C. neoformans biofilms in a concentration-dependent manner, accompanied by major structural disruption. We investigated the molecular response of C. neoformans and C. deuterogattii to brilacidin by quantitative proteomics, which revealed species-specific responses. Brilacidin primarily affected proteins involved in sterol metabolism, oxidative stress, and cell wall biosynthesis. These results deepen our understanding of the anti- Cryptococcus effects of brilacidin and reinforce the potential of this drug as a highly promising antifungal agent for the treatment of cryptococcosis. IMPORTANCE Cryptococcosis is a life-threatening fungal disease that mainly affects immunocompromised individuals and remains difficult to treat due to toxic drugs, limited therapeutic options, and the emergence of resistance. This study deepens the understanding of brilacidin as a promising antifungal candidate against the causative agents of cryptococcosis. Brilacidin exhibits potent fungicidal activity at low concentrations with minimal toxicity to host cells and enhances the efficacy of amphotericin B, allowing for reduced doses that may mitigate adverse effects. Furthermore, brilacidin disrupts key fungal structures, including the capsule and biofilms, and induces distinct cellular stress responses. By providing mechanistic and translational insights, this work supports the development of safer and more effective therapeutic strategies for this neglected and often fatal fungal infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsCryptococcus neoformansCryptococcosisCryptococcusAnimalsBiofilmsMicrobial Sensitivity TestsMiceMacrophagesAmphotericin BDrug Synergism

Stichwörter der Autor:innen

Cryptococcus deuterogattiiCryptococcus neoformansantifungal activityantifungal drugs synergismbiofilmbrilacidincryptococcosisproteomics

Substanzen

Antifungal AgentsAmphotericin B

Autor:innen und Institutionen

  • Instituto Carlos Chagas, Fundação Oswaldo Cruz (Fiocruz), Curitiba, Brazil.
  • Analytical Biochemistry and Proteomics Unit, Instituto de Investigaciones Biológicas Clemente Estable, Institut Pasteur de Montevideo, Montevideo, Uruguay.
  • Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Department of Microbiology, Immunology, and Parasitology, Discipline of Cellular Biology, Federal University of Sao Paulo (UNIFESP), Sao Paulo, Brazil.

ORCID-Profile: Paulo C Carvalho, Marcio L Rodrigues, Haroldo C de Oliveira

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • National Institute of Allergy and Infectious Diseases
  • NIAID NIH HHS
  • Global AMR Innovation Fund (GAMRIF) initiative
  • FOCEM-COF
  • NAPI Protemica from Araucaria Foundation 2013; Parana
  • Fundação de Amparo à Pesquisa do Estado de São Paulo
  • Program for Research Stimulation (PEP) of the Carlos Chagas Institute of Fiocruz

Zitieren

APA

Bezerra, B. T., Mellon, D. A., Souza, C. M., Castelli, R. F., Camillo-Andrade, A. C., Santos, M. D. M., Carvalho, P. C., Rodrigues, M. L., & Oliveira, H. C. (2026). Cellular and molecular responses of Cryptococcus to brilacidin. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00138-26

Vancouver

Bezerra BT, Mellon DA, Souza CM, Castelli RF, Camillo-Andrade AC, Santos MDM, et al. Cellular and molecular responses of Cryptococcus to brilacidin. Microbiology Spectrum. 2026. doi:10.1128/spectrum.00138-26

BibTeX
@article{Bezerra2026,
  author = {Bezerra, Barbara T and Mellon, Daniel A and Souza, Cássia M and Castelli, Rafael F and Camillo-Andrade, Amanda C and Santos, Marlon D M and Carvalho, Paulo C and Rodrigues, Marcio L and Oliveira, Haroldo C de},
  title = {Cellular and molecular responses of Cryptococcus to brilacidin},
  journal = {Microbiology Spectrum},
  year = {2026},
  doi = {10.1128/spectrum.00138-26}
}
Kostenlos starten →